Recent Stages II-III Multiple Myeloma News

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (January 31, 2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma... Continue Reading

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma (December 8, 2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly... Continue Reading

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (July 22, 2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib),... Continue Reading

Treanda/Velcade/Dexamethasone Produces High Response Rate in Relapsed/Refractory Multiple Myeloma (March 10, 2014)

The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results... Continue Reading

Continuous Revlimid/Lose-Dose Dexamethasone Improves Outcomes in Newly Diagnosed Multiple Myeloma (March 3, 2014)

Among people with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation, continuous treatment with Revlimid® (lenalidomide) and low-dose dexamethasone results in better overall... Continue Reading

Revlimid After Stem Cell Transplantation Delays Progression of Myeloma, but Does Not Improve Overall Survival (February 24, 2014)

In a Phase III clinical trial among patients who had undergone stem cell transplantation for multiple myeloma, post-transplant maintenance therapy with Revlimid® (lenalidomide) significantly delayed cancer... Continue Reading

Kyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed Multiple Myeloma (November 25, 2013)

The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple myeloma,... Continue Reading

Next Page »